Effects of Neurorehabilitation on Upper Limb Performance and on Fatigue in People With Multiple Sclerosis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Multiple Sclerosis
- Sponsor
- Fondazione Don Carlo Gnocchi Onlus
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Change from Baseline in Heart Rate at 2 and 4 months
- Last Updated
- 9 years ago
Overview
Brief Summary
In Multiple Sclerosis the multiplicity of physical and psychological dysfunctions have been shown to exhibit a number of life-altering problems such as fatigue, limb weakness, alteration of upper extremity fine motor coordination, loss of sensation, spasticity. These problems affect performance of many daily living activities (ADL) such as dressing, bathing, self-care, and writing, thus reducing functional independence and self-rated quality of life.
Twenty people with Multiple Sclerosis will receive neurorehabilitation treatment comprising a combination of aerobic training and upper limb task-oriented training.
The aim of this pilot crossover study is to evaluate the effects of neurorehabilitation on upper limb performance and on fatigue in People with Multiple Sclerosis.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of Multiple Sclerosis
- •no relapses in the last three months
- •Expanded Disability Status Scale (EDSS) ≤ 8;
Exclusion Criteria
- •subjects with relapses
- •worsening of the pathology in the last three months
- •subjects with cognitive and psychiatric disturbances
- •subjects with cardiovascular disease
Outcomes
Primary Outcomes
Change from Baseline in Heart Rate at 2 and 4 months
Time Frame: baseline, then participants were followed for the duration the outpatient treatment protocol, an average of 8 weeks, and at follow up 2 months after the end of the treatment protocol
Change from Baseline in 9-hole peg test at 2 and 4 months
Time Frame: baseline, then participants were followed for the duration the outpatient treatment protocol, an average of 8 weeks, and at follow up 2 months after the end of the treatment protocol